Landmark approval for pancreatic cancer; Reactions to Lilly’s Phase 1 secrecy; and morenews2026-08-29T10:00:51+00:00August 29th, 2026|Endpoints News|
#ESC26: Novartis pushes ahead with its IL-6 inhibitor despite Novo’s failurenews2026-08-29T06:55:35+00:00August 29th, 2026|Endpoints News|
FDA approves Takeda, Protagonist drug for rare blood disordernews2026-08-28T22:15:30+00:00August 28th, 2026|Endpoints News|
Mounjaro scores FDA approval to reduce CV risk; Teva to buy an approved drugnews2026-08-28T14:58:50+00:00August 28th, 2026|Endpoints News|
BioNTech, Genentech terminate Phase 2 of personalized mRNA cancer vaccinenews2026-08-28T14:49:15+00:00August 28th, 2026|Endpoints News|
#ESC26: CRISPR Therapeutics to pursue highest dose of its lipid lowering gene editing therapynews2026-08-28T14:30:23+00:00August 28th, 2026|Endpoints News|
Roche bets $1B+ on DualityBio’s ADC tech to tackle TOPO1 resistancenews2026-08-28T11:30:02+00:00August 28th, 2026|Endpoints News|
Daiichi Sankyo to give commercial team a makeover; Novo Nordisk’s GPCR partner finds CMOnews2026-08-28T11:00:21+00:00August 28th, 2026|Endpoints News|
#ESC26: Data in hand, Cytokinetics looks to expanded Myqorzo approvalnews2026-08-28T09:45:14+00:00August 28th, 2026|Endpoints News|
#ESC26: Trial failure clouds future of AstraZeneca’s heart disease gene silencernews2026-08-28T09:10:19+00:00August 28th, 2026|Endpoints News|
